{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:35:54Z","timestamp":1768520154804,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.msard.2020.102707","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T18:02:00Z","timestamp":1609178520000},"page":"102707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"48","author":[{"given":"Liang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingzi","family":"ZhangBao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuechun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanzhen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2020.102707_bib0001","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41598-017-00860-y","article-title":"Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder","volume":"7","author":"Chen","year":"2017","journal-title":"Scientific reports"},{"issue":"10206","key":"10.1016\/j.msard.2020.102707_bib0002","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"11","key":"10.1016\/j.msard.2020.102707_bib0003","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"issue":"3","key":"10.1016\/j.msard.2020.102707_bib0004","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3348\/kjr.2016.17.3.339","article-title":"How to Develop, Validate, and Compare Clinical Prediction Models Involving Radiological Parameters: Study Design and Statistical Methods","volume":"17","author":"Han","year":"2016","journal-title":"Korean journal of radiology"},{"issue":"3","key":"10.1016\/j.msard.2020.102707_bib0005","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/CON.0000000000000337","article-title":"Neuromyelitis Optica Spectrum Disorders","volume":"22","author":"Katz Sand","year":"2016","journal-title":"Continuum (Minneapolis, Minn.)"},{"key":"10.1016\/j.msard.2020.102707_bib0006","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.msard.2017.08.005","article-title":"Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study","volume":"17","author":"Kessler","year":"2017","journal-title":"Multiple sclerosis and related disorders"},{"issue":"1","key":"10.1016\/j.msard.2020.102707_bib0007","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"3","key":"10.1016\/j.msard.2020.102707_bib0008","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"key":"10.1016\/j.msard.2020.102707_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101868","article-title":"Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder","volume":"38","author":"Kunchok","year":"2020","journal-title":"Multiple sclerosis and related disorders"},{"issue":"9451","key":"10.1016\/j.msard.2020.102707_bib0010","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.msard.2020.102707_bib0011","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-012-2044-y","article-title":"Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature","volume":"31","author":"Matsubara","year":"2012","journal-title":"Clinical rheumatology"},{"issue":"3","key":"10.1016\/j.msard.2020.102707_bib0012","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA neurology"},{"key":"10.1016\/j.msard.2020.102707_bib0013","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock","year":"2014","journal-title":"BMC neurology"},{"issue":"6","key":"10.1016\/j.msard.2020.102707_bib0014","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/s10165-009-0218-5","article-title":"Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study","volume":"19","author":"Miyasaka","year":"2009","journal-title":"Modern rheumatology"},{"key":"10.1016\/j.msard.2020.102707_bib0015","first-page":"24","article-title":"Pregnancy and Systemic Lupus Erythematosus. Best practice & research","volume":"64","author":"Petri","year":"2020","journal-title":"Clinical obstetrics & gynaecology"},{"issue":"7","key":"10.1016\/j.msard.2020.102707_bib0016","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"The New England journal of medicine"},{"issue":"1","key":"10.1016\/j.msard.2020.102707_bib0017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ecco-jcc\/jjv175","article-title":"Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues","volume":"10","author":"Schmidt","year":"2016","journal-title":"Journal of Crohn's & colitis"},{"issue":"11","key":"10.1016\/j.msard.2020.102707_bib0018","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/00007890-199506000-00018","article-title":"Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell","volume":"59","author":"Tamura","year":"1995","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.msard.2020.102707_bib0019","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/1352458514546793","article-title":"Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders","volume":"21","author":"Tanaka","year":"2015","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"issue":"5","key":"10.1016\/j.msard.2020.102707_bib0020","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/j.msard.2020.102707_bib0021","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jocn.2019.02.004","article-title":"Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis","volume":"63","author":"Wang","year":"2019","journal-title":"Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia"},{"issue":"2","key":"10.1016\/j.msard.2020.102707_bib0022","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2020.102707_bib0023","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"The New England journal of medicine"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820307811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:50:44Z","timestamp":1761900644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820307811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":23,"alternative-id":["S2211034820307811"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102707","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102707"}}